IDXX

SEC source: 0001567619-19-010453 · doc1.xml · derivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,793

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-19-010452 · doc1.xml · derivative · entry 2

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-19-010452 · doc1.xml · derivative · entry 1

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,745

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-19-010451 · doc1.xml · derivative · entry 2

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-19-010451 · doc1.xml · derivative · entry 1

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 891

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors

SEC source: 0001567619-19-010450 · doc1.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-19-010450 · doc1.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,958

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-19-010042 · doc1.xml · nonDerivative · entry 1

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,195

F1 · balance_after: Includes 32 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 29, 2019.

SEC source: 0001567619-19-009907 · doc1.xml · derivative · entry 7

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,820

Underlying: Common Stock · 28,000 shares

Expires 2020-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable.

F5 · derivative.exercise_date: Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-009907 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,025,916

SEC source: 0001567619-19-009907 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,026,016

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $249.00 to a high of $250.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-009907 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,039,916

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $248.30 to a high of $248.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-009907 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,051,316

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $247.23 to a high of $248.225 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-009907 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,053,916

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 32 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 29, 2019.

SEC source: 0001567619-19-009908 · doc1.xml · derivative · entry 8

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,504 shares

Expires 2019-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F9 · derivative.exercise_date: Grant of option to buy 3,752 shares of IDEXX Laboratories, Inc. common stock that became exercisable one installment on May 9, 2013 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 7

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,528

F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person.

F8 · price: Represents the weighted average price of the shares sold ranging from a low of $248.765 to a high of $248.8475 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 6

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,157

F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person.

F7 · price: Represents the weighted average price of the shares sold ranging from a low of $247.745 to a high of $247.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 5

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,928

F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person.

F6 · price: Represents the weighted average price of the shares sold ranging from a low of $246.61 to a high of $247.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 4

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,153

F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person.

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $245.35 to a high of $246.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 3

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,528

F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person.

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $244.00 to a high of $244.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 2

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,828

F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person.

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $242.42 to a high of $243.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 1

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,032

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 32 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 29, 2019.

SEC source: 0001567619-19-009682 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,108

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-009681 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,767

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($5,937.50) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-009680 · doc1.xml · nonDerivative · entry 1

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 649

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-005827 · doc1.xml · nonDerivative · entry 1

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,178

SEC source: 0001567619-19-005515 · doc1.xml · nonDerivative · entry 4

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,389

F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $208.00 to a high of $208.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-19-005515 · doc1.xml · derivative · entry 5

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 708

Underlying: Common Stock · 1,156 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-005515 · doc1.xml · nonDerivative · entry 3

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,223

SEC source: 0001567619-19-005515 · doc1.xml · nonDerivative · entry 2

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,695

F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $211.00 to a high of $211.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-19-005515 · doc1.xml · nonDerivative · entry 1

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,918

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-005513 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,025,884

SEC source: 0001567619-19-005272 · doc1.xml · derivative · entry 4

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,322 shares

Expires 2023-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy 1,661 shares of IDEXX Laboratories, Inc. common stock that became exercisable on the fifth anniversary of the date of grant without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-005272 · doc1.xml · nonDerivative · entry 2

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,732

F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $211.5801 to a high of $211.5810 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-19-005272 · doc1.xml · nonDerivative · entry 1

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,468

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-005271 · doc1.xml · derivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,612 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy 806 shares of IDEXX Laboratories, Inc. common stock that became exercisable on the fifth anniversary of the date of grant without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-005271 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,033,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-004921 · doc1.xml · nonDerivative · entry 7

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,146

SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 18

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,293

Underlying: Common Stock · 1,714 shares

Expires 2028-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F9 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2019.

SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 17

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,948

Underlying: Common Stock · 2,219 shares

Expires 2027-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F8 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2018.

SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 16

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,474

Underlying: Common Stock · 1 shares

Expires 2026-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F7 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017.

SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 15

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,927

Underlying: Common Stock · 4,700 shares

Expires 2026-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F7 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017.

SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 14

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,864

Underlying: Common Stock · 100 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F6 · derivative.exercise_date: Grant of option to buy 3,140 shares of Issuer common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 13

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,866

Underlying: Common Stock · 2,866 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F5 · derivative.exercise_date: Grant of option to buy 7,165 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 12

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,762

F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $209.10 to a high of $209.37 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 11

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,476

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 10

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,762

F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $208.91 to a high of $209.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 9

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,981

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 8

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,762

SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 7

Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,763

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.